Tetraphase's drug belongs to the same class as Tetracycline, so it's not a novel antibiotic. It met the primary endpoint in complicated intra-abdominal infections, but failed complicated urinary tract infections . I don't think CTIX is targeting those areas, at least not in the near term.

Quote:

---

Interesting fallout for Tetraphase. I'm fuzzy with the medical side, but their treatment addressing gram-negative bacteria failed in PH III, after they essentially reported it was a success. An omen or open door for CTIX?

---